SU-E-T-422: Lung SBRT Using Cyberknife: Technique and Treatment Outcome

Area of Science:

• Oncology
• Radiotherapy
• Medical Physics

Background:

• Lung cancer remains a leading cause of cancer-related deaths globally.
• Stereotactic Body Radiotherapy (SBRT) has emerged as a promising treatment modality for lung cancer.
• Cyberknife robotic system offers advanced precision in delivering SBRT.

Purpose of the Study:

• To present the clinical experience and outcomes of Cyberknife stereotactic body radiotherapy (CK-SBRT) for primary and secondary lung cancers.
• To evaluate the efficacy and safety of CK-SBRT in a cohort of 79 patients treated between 2009 and 2011.
• To assess the treatment response and survival rates in patients with lung cancer treated with CK-SBRT.

Main Methods:

• Retrospective analysis of 79 patients (83 sites) treated with CK-SBRT.
• Utilized Cyberknife robotic system with various tracking techniques (Synchrony, XsiteLung, XsightSpine).
• Prescription doses ranged from 25-55Gy in 3-5 fractions, with tight planning target volume (PTV) margins and 80% isodose line prescription.

Main Results:

• High overall response rate of 98.8% (73.5% complete response).
• One-year local failure-free survival rates: 84% for primary, 76% for recurrent, and 100% for metastatic lung tumors.
• Low toxicity profile observed, with infrequent instances of chest wall pain and radiation pneumonitis.

Conclusions:

• CK-SBRT demonstrates a reasonable treatment outcome with tight PTV margins and high dosimetric coverage.
• The treatment approach appears effective and safe for managing primary and secondary lung cancers.
• Further research is ongoing to correlate PTV margins, dosimetric coverage, and treatment outcomes.